Causality assessment methods in drug induced liver injury: Strengths and weaknesses

被引:144
|
作者
Garcia-Cortes, Miren [2 ]
Stephens, Camilla
Isabel Lucena, M. [1 ]
Fernandez-Castaner, Alejandra [2 ]
Andrade, Raul J. [2 ]
机构
[1] Hosp Univ Virgen de la Victoria, Fac Med, Dept Farmacol,Coordinating Ctr, Serv Farmacol Clin,Grp Estudio Hepatopatias Asoci, Malaga 29071, Spain
[2] Hosp Univ Virgen de la Victoria, Serv Aparato Digest, Unidad Hepatol, Malaga 29010, Spain
关键词
Drug induced liver injury; Hepatotoxicity; CIOMS/RUCAM scale; Causality assessment methods; Diagnosis; Risk factors; Limitations; DIAGNOSTIC SCALE; ADVERSE REACTIONS; HEPATOTOXICITY; MANAGEMENT; PROBABILITY; VALIDATION; FAILURE; RISK;
D O I
10.1016/j.jhep.2011.02.007
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Diagnosis of drug-induced liver injury (DILI) remains a challenge and eagerly awaits the development of reliable hepatotoxicity biomarkers. Several methods have been developed in order to facilitate hepatotoxicity causality assessments. These methods can be divided into three categories: (1) expert judgement, (2) probabilistic approaches, and (3) algorithms or scales. The last category is further divided into general and liver-specific scales. The Council for International Organizations of Medical Sciences (CIOMS) scale, also referred to as the Roussel Uclaf Causality Assessment Method (RUCAM), although cumbersome and difficult to apply by physicians not acquainted with DILI, is used by many expert hepatologists, researchers, and regulatory authorities to assess the probability of suspected causal agents. However, several limitations of this scale have been brought to light, indicating that a number of adjustments are needed. This review is a detailed timely criticism to alert the readers of the limitations and give insight into what would be needed to improve the scale. Instructions on how to approach DILI diagnosis in practice are provided, using CIOMS as an aid to emphasize the topics to be addressed when assessing DILI cases. Amendments of the CIOMS scale in the form of applying authoritative evidence-based criteria, a simplified scoring system and appropriate weighting given to individual parameters based on statistical evaluations with large databases will provide wider applicability in the clinical setting. (C) 2011 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:683 / 691
页数:9
相关论文
共 50 条
  • [41] Strengths and weaknesses of different challenge methods
    Nordmo, R
    FISH VACCINOLOGY, 1997, 90 : 303 - 309
  • [42] Need for Causality Assessment Tool for Drug-induced Acute Kidney Injury
    Duru, Merve
    Meydan, Osman
    Kaya, Mustafa
    Gulmez, Sinem Ezgi
    CLINICAL THERAPEUTICS, 2019, 41 (09) : 1894 - 1897
  • [43] Drug-induced Liver Injury Assessment in VigiBase
    China, Joana Felix
    Baiao, Rita
    Tarapues, Monica
    Rudolph, Annette
    DRUG SAFETY, 2024, 47 (12) : 1335 - 1336
  • [44] UTILITY OF A NOVEL DRUG INDUCED LIVER INJURY CAUSALITY ASSESSMENT TOOL (DILI-CAT) FOR ADJUDICATION OF DILI IN DRUG DEVELOPMENT.
    Faasld, Hans L. Tillmann. Md.
    Rockey, Don C.
    Suzuki, Ayako
    Merz, Michael
    Herrmann, Richard
    HEPATOLOGY, 2020, 72 : 731A - 732A
  • [45] Antituberculosis drug-induced liver injury (ATDILI): assessment of drug causality and pathogenesis with lymphocyte transformation test (LTT) and pharmacogenetics (PHGX)
    Garcia Garcia, Irene
    Rodriguez Mariblanca, Amelia
    Dapia Garcia, Irene
    Diaz Garcia, Lucia
    Martinez De Soto, Lucia
    Queiruga Parada, Javier
    Monserrat Villatoro, Jaime
    Borobia, Alberto
    Ramirez Garcia, Elena
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2018, 123 : 38 - 38
  • [46] Comparison of two clinical scales in the causality assessment of drug induced liver disease
    Garcia-Cortes, M.
    Pachkoria, K.
    Lucena, M. I.
    Andrade, R.
    Camargo, R.
    Alcantara, R.
    Hidalgo, R.
    JOURNAL OF HEPATOLOGY, 2006, 44 : S253 - S253
  • [47] Drug-Induced Liver Injury: Expanding Our Knowledge by Enlarging Population Analysis With Prospective and Scoring Causality Assessment
    Teschke, Rolf
    Andrade, Raul J.
    GASTROENTEROLOGY, 2015, 148 (07) : 1271 - 1273
  • [48] Monocyte-derived hepatocyte-like cells for causality assessment of idiosyncratic drug-induced liver injury
    Benesic, Andreas
    Leitl, Alexandra
    Gerbes, Alexander L.
    GUT, 2016, 65 (09) : 1555 - 1563
  • [49] Different written assessment methods: what can be said about their strengths and weaknesses?
    Schuwirth, LWT
    van der Vleuten, CPM
    MEDICAL EDUCATION, 2004, 38 (09) : 974 - 979
  • [50] Causality Evaluation of Drug-Induced Liver Injury in Newborns and Children in the Intensive Care Unit Using the Updated Roussel Uclaf Causality Assessment Method
    Ye, Ling
    Feng, Zeying
    Huang, Longjian
    Guo, Chengjun
    Wu, Xiong
    He, Li
    Tan, Wei
    Wang, Yi
    Wu, Xuehong
    Hu, Biwen
    Li, Tong
    Yang, Guoping
    Chengxian, Guo
    He, Qingnan
    FRONTIERS IN PHARMACOLOGY, 2021, 12